The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis.

IF 5.3 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Biologics : Targets & Therapy Pub Date : 2018-11-08 eCollection Date: 2018-01-01 DOI:10.2147/BTT.S176806

S C Heslinga, T C Konings, I E van der Horst-Bruinsma, O Kamp, V P van Halm, Hacm de Bruin-Bon, M J Peters, M T Nurmohamed

{"title":"The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis.","authors":"S C Heslinga, T C Konings, I E van der Horst-Bruinsma, O Kamp, V P van Halm, Hacm de Bruin-Bon, M J Peters, M T Nurmohamed","doi":"10.2147/BTT.S176806","DOIUrl":null,"url":null,"abstract":"Background: Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study was to find the effects of 1-year treatment with golimumab 50 mg subcutaneously once per month on systolic and diastolic LV dysfunction in AS patients.Methods: Forty consecutive AS patients were treated with TNF-α blocking therapy for 1 year. Transthoracic echocardiography was performed in all patients at baseline and after 1 year of treatment.Results: Diastolic LV function improved after treatment in four out of six (67%) AS patients who completed follow-up (P=0.125), and did not develop or worsen in any of the other patients. Treatment with TNF-α blocking therapy had no effect on systolic LV function.Conclusion: These findings give support to the hypothesis that diastolic LV dysfunction improves during treatment with TNF-α blocking therapy.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"12 ","pages":"143-149"},"PeriodicalIF":5.3000,"publicationDate":"2018-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/BTT.S176806","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biologics : Targets & Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/BTT.S176806","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study was to find the effects of 1-year treatment with golimumab 50 mg subcutaneously once per month on systolic and diastolic LV dysfunction in AS patients.

Methods: Forty consecutive AS patients were treated with TNF-α blocking therapy for 1 year. Transthoracic echocardiography was performed in all patients at baseline and after 1 year of treatment.

Results: Diastolic LV function improved after treatment in four out of six (67%) AS patients who completed follow-up (P=0.125), and did not develop or worsen in any of the other patients. Treatment with TNF-α blocking therapy had no effect on systolic LV function.

Conclusion: These findings give support to the hypothesis that diastolic LV dysfunction improves during treatment with TNF-α blocking therapy.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

高利单抗治疗对强直性脊柱炎患者左室收缩和舒张功能的影响。

背景:强直性脊柱炎(AS)患者左室舒张期功能障碍更为普遍。肿瘤坏死因子α (TNF-α)阻断治疗是一种强效抗炎药物，对AS舒张期左室功能的影响尚不清楚。该研究的目的是发现每月1次golimumab 50mg皮下治疗1年对AS患者收缩和舒张期左室功能障碍的影响。方法:连续40例AS患者接受TNF-α阻断治疗1年。所有患者在基线和治疗1年后均行经胸超声心动图检查。结果:6例AS患者中有4例(67%)完成随访(P=0.125)，治疗后左室舒张功能改善，其他患者无进展或恶化。TNF-α阻断治疗对收缩期左室功能无影响。结论:这些发现支持了舒张期左室功能障碍在TNF-α阻断治疗期间得到改善的假设。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊